OGT to Develop Microarrays for HIV-AIDS Vaccine Research

Dec 05, 2006

NEW YORK (GenomeWeb News) - Oxford Gene Technology today said it will design an optimized oligonucleotide microarray for the Innate Discovery Team, part of the Center for IV-AIDS Vaccine Immunology.

The center will use the microarrays to study genes involved in the cellular immune response of early-stage HIV-infected patients.

OGT said the microarrays will be printed using its ink jet in situ synthesis platform for parallel analysis of multiple samples.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Breaking News

The Scan

Warren Releases Genetic Ancestry Results

Senator Elizabeth Warren (D-Mass.) has released the results of a genetic ancestry analysis, the Boston Globe reports.

Thirty-One Recommended for Removal

Retraction Watch's Ivan Oransky and Adam Marcus report that Harvard Medical School and Brigham and Women's Hospital have recommended that more than 30 papers from a former researcher be retracted.

Thomas Steitz Dies

Thomas Steitz, who won the 2009 chemistry Nobel Prize for his ribosome work, has died, the Washington Post reports.

This Week in PLOS

In PLOS this week: mechanisms for genes implicated in coronary artery disease, rumen microbes and host genetics influence cow methane production, and more.

Featured White Papers

Tissue Section Imaging

In Vivo Validation of Optical Probes

Ex Vivo Imaging Quick Start Guide

Probe Design and In Vitro Validation Quick Start Guide

Oct

17

Featured Webinar

Reliable RNA-Seq Expression Profiling from Low-Quality FFPE Biobank Samples

This webinar will present a method for RNA-seq expression analysis of FFPE-derived RNA samples that are too degraded for successful application of standard RNA-seq techniques.

Oct

25

Featured Webinar

A Comprehensive Strategy for Evaluating NGS Liquid Biopsy and Tumor Tissue Assays

This webinar will detail a comprehensive strategy that a lab has put in place to evaluate NGS oncology assays for genomic tumor profiling of plasma and tissue samples.

Main menu